Novel Antigen for Use as Vaccine Against Nematode Infection
Posted Jul 11 2010 5:00pm
Description of Invention: This invention describes a new vaccine against Strongyoides stercoralis, which establishes a parasitic infection that affects an estimated 100-200 million people worldwide. The potential for fatal disease associated with S. stercoralis infection and the difficulty in treating hyperinfection underscores the need for prophylactic vaccines against the disease. This vaccine uses S. stercoralis immunoreactive antigen (SsIR); a novel antigen capable of providing 70-90 % protection for mice immunized with the antigen. In addition, sera from immunized mice have also been used to effectively protect naive mice from infection.
The invention may also have potential use in diminishing allergic responses, as Strongyoides stercoralis infection has been shown to reduce the murine response to allergens. Consequently, SsIR may be used to immunize individuals and reduce the allergic response. The antigen may also be used to identify homologous antigens from other parasitic nematodes that may be important for vaccine development.
Applications:
Vaccines against S. stercoralis infection
Discovery and use of other anti-parasitic antigens for vaccines
Potential for allergy therapy
Development Status: Early stage
Inventors: Thomas B Nutman (NIAID) David Abraham (Thomas Jefferson University)
Collaborative Research Opportunity: The Laboratory of Parasitic Diseases at NIAID is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Thomas Nutman, PhD at tnutman@niaid.nih.gov or Johanna Schneider, PhD at schneiderjs@niaid.nih.gov for more information.
For Additional Information Please Contact: Susan Ano Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: anos@mail.nih.gov Phone: 301-435-5515 Fax: 301-402-0220
Description of Invention:
This invention describes a new vaccine against Strongyoides stercoralis, which establishes a parasitic infection that affects an estimated 100-200 million people worldwide. The potential for fatal disease associated with S. stercoralis infection and the difficulty in treating hyperinfection underscores the need for prophylactic vaccines against the disease. This vaccine uses S. stercoralis immunoreactive antigen (SsIR); a novel antigen capable of providing 70-90 % protection for mice immunized with the antigen. In addition, sera from immunized mice have also been used to effectively protect naive mice from infection.
The invention may also have potential use in diminishing allergic responses, as Strongyoides stercoralis infection has been shown to reduce the murine response to allergens. Consequently, SsIR may be used to immunize individuals and reduce the allergic response. The antigen may also be used to identify homologous antigens from other parasitic nematodes that may be important for vaccine development.
Applications:
Development Status:
Early stage
Inventors:
Thomas B Nutman (NIAID)
David Abraham (Thomas Jefferson University)
Patent Status:
HHS, Reference No. E-084-2010/0
US, Application No. 61/301,426 filed 04 Feb 2010
Licensing Status:
Available for licensing
Collaborative Research Opportunity:
The Laboratory of Parasitic Diseases at NIAID is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Thomas Nutman, PhD at tnutman@niaid.nih.gov or Johanna Schneider, PhD at schneiderjs@niaid.nih.gov for more information.
Portfolios:
Infectious Diseases
Infectious Diseases - Therapeutics
Infectious Diseases - Vaccines
For Additional Information Please Contact:
Susan Ano Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: anos@mail.nih.gov
Phone: 301-435-5515
Fax: 301-402-0220
Ref No: 2133
Updated: 07/2010